

Fishers Lane, Room 9C-26, Rockville, MD 20857, 301-443-6470.

Name of Committee: National Institute of Mental Health Initial Review Group, Perception and Cognition Review Committee.

Date: February 18-19, 1999.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: One Washington Circle, 1 Washington Circle, NW, Washington, DC 20037.

Contact Person: Russell E. Martenson, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9-101, Rockville, MD 20857, 301-443-3936.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: January 14, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-1428 Filed 1-21-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Mental Health Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Mental Health Council.

Date: February 4-5, 1999.

Closed: February 4, 1999, 10:30 am to 5:00 pm.

Agenda: To review and evaluate grant applications and/or proposals.

Place: Parklawn Building, Conference Room E, 5600 Fishers Lane, Rockville, MD 20857.

Open: February 5, 1999, 8:00 am to 2:45 pm.

Agenda: Presentation of NIMH Director's Report and discussion of NIMH program and policy issues.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 6, Bethesda, MD 20892.

Contact Person: Jane A. Steinberg, PhD, Executive Secretary, Acting Director, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9-105, Rockville, MD 20857, 301-443-3367.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: January 14, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-1429 Filed 1-21-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Co-Exclusive License: *erbB-2/HER2/neu* Gene Segments, Probes, Recombinant DNA and Kits for Detection

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a co-exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial Number 08/475,035, entitled "*erbB-2* Gene Segments, Probes, Recombinant DNA and Kits for Detection" filed June 7, 1995, and U.S. Patent Application Serial Number 07/110,791, entitled "Human Gene Related To But Distinct From EGF Receptor", filed October 21, 1987 to Ventana Medical Systems, Inc., Having a place of business in Tucson, AZ. This announcement supersedes the prior

Notice of Intent to Grant published on October 19, 1998. The patent rights in this invention have been assigned to the United States America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 23, 1999 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Susan S. Rucker, J.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 245; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: In an effort to identify genes which are associated with cancer, the invention described in these patent applications includes a gene, related to the epidermal growth factor, now known as *erbB-2/HER2/neu*. Research related to this gene has indicated that the gene is implicated in breast and other cancers. While the amplification of this gene has been demonstrated to have prognostic value with respect to breast cancer additional development is needed to determine whether or not the gene has value as a prognostic indicator for other types of cancer or may serve as an indicator which can be sued to select the proper course of treatment for breast and other cancers.

The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the development of nucleotide-based diagnostic and prognostic uses, regulated by the Food and Drug Administration, of the invention for cancers other than breast cancer including, but not necessarily limited to, prostate, ovarian, and bladder cancers.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released